Mark tweets at @Mark_Blaskovich
Dr. Mark Blaskovich is an IMB Fellow at the Institute for Molecular Bioscience at The University of Queensland.
He has extensive medicinal chemistry expertise resulting from more than 16 years of industrial drug development experience.
As Chief Operating Officer at Mimetica (Australia), he managed the drug discovery and development program for melanocortin-5 receptor antagonists, leading to a compound currently in Phase II human trials.
In his previous role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate that inhibited protein tyrosine phosphatase 1B for the treatment of diabetes, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs.
Mark is currently developing new antibiotics to treat drug resistant pathogens and new methods to diagnose infections.
He has published more than 70 articles, is an inventor on 11 families of patents, and is author of 'The Handbook on Syntheses of Amino Acids'.